The AUCs for early recurrence were 0.616 (95% CI: 0.554–0.675), 0.569 (95% CI: 0.507–0.629), and 0.575 (95% CI: 0.512–0.635) for the TPS model, BCLC stage, and AJCC TNM stage, respectively (Figure S2B), but results of the DeLong's test showed that there seemed no statistic difference in the ability of the TPS model in predicting early recurrence in the AFP‐negative HCC patients with cirrhosis after liver resection compared with BCLC stage (p = 0.266) and AJCC TNM stage (p = 0.318). This evidence concerns the gene AFP and hepatocellular carcinoma.